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Abstract
Background: Cervical cancer is the most common female cancer in Bhutan, the first low/middle-income country to
implement a national human papillomavirus (HPV) vaccination programme.
Methods: To provide a robust baseline for future evaluations of vaccine effectiveness, cervical cell specimens were
obtained from 2,505 women aged 18–69 years from the general population, and biopsies from 211 cervical
intraepithelial neoplasia grade 3 (CIN3) and 112 invasive cervical cancer (ICC) cases. Samples were tested for HPV
using GP5+/6+ PCR.
Results: Among the general population, HPV prevalence was 26%, being highest (33%) in women ≤24 years, but
remaining above 15% in all age-groups. Determinants of HPV included age, marital status, and number of sexual
partners. Among the eight percent with cytological abnormalities, 24 CIN3 and 4 ICC were histologically confirmed.
Even after additional testing with a sensitive E7 PCR, no infections with vaccine-targeted HPV types were detected
in the few vaccinated women (n = 34) compared to 6% prevalence in unvaccinated women of similar age
(p = 0 · 215).
Conclusion: Based upon type-specific prevalence among biopsies, at least 70% of ICC in Bhutan are theoretically
preventable by HPV16/18 vaccination, but screening programmes should be expanded among older women, who
have an important underlying burden of CIN3 and ICC.
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Background
In the Himalayan kingdom of Bhutan, cervical cancer rep-
resents the most common cancer among females, with an
age-standardised incidence rate of approximately 13 cases
per 100,000 person years [1], one of the highest in Asia.
Given such a high burden of disease and the limited cover-
age of cervical screening, Bhutan became the first low- or
middle-income country (LMIC) to initiate a national vac-
cination programme against human papillomavirus (HPV),
the necessary cause of cervical cancer. In 2010, over
130,000 doses of quadrivalent (HPV16/18/6/11) HPV
vaccine were administered, primarily at schools. The 3
dose vaccination coverage is estimated at 92% among
12–18 year old girls [2]. Since 2011, 12-year old girls
have continued to be vaccinated.
The impact of the vaccine programme on cervical can-
cer will not be seen for at least 20 years and, therefore,
short-term evidence of vaccine programme effectiveness is
crucial to encourage national planners to sustain HPV
vaccination services. Hence, the Bhutan Ministry of
Health, in collaboration with the International Agency for
Research on Cancer (IARC), initiated a series of studies to
evaluate the short term impact of HPV vaccine on HPV
prevalence.
As no data existed on the burden of HPV among women
in Bhutan, a baseline study of the prevalence of, and risk
factors for, HPV infection prior to vaccination was initi-
ated in 2011 according to the standardised protocol of the
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IARC HPV prevalence surveys [3]. Cervicovaginal samples
were collected from women aged 18–69 years living in the
capital, Thimphu, with a particular effort to oversample
young (≤25 years) women. In addition, biopsy/tissue speci-
mens were collected from women diagnosed with cervical
intraepithelial neoplasia grade 3 (CIN3) and invasive
cervical cancer (ICC), for HPV detection and genotyping.
Methods
General female population
Between December 2011 and October 2012, a survey was
conducted by the Ministry of Health of Bhutan in colla-
boration with the IARC, Lyon, France. The study aim was
to enrol 2,500 women from the general population using
an age-stratified approach, namely 1,000 women aged
below 25 years old, 500 women aged 25 to 29 years old,
200 women in each five-year age group between 30–34
and 45–49 years, and 200 women aged ≥50 years. Over-
representation of young women was done in order to
allow robust assessment of vaccine-induced changes in
HPV prevalence in a repeat survey after 5 years. All men-
tally and physically competent women were eligible for
the study, regardless of their marital status.
Study procedures were performed in the Reproductive
Health Departments of Jigme Dorji Wangchuck National
Referral Hospital (JDWNRH) in Thimphu, and in the
hospital of Lungtenphu, a satellite town of Thimphu. To
reach a broad and representative sample of the population
living around the two hospitals, women were recruited in
two ways: 1) Women residing in the pre-defined areas sur-
rounding the two hospitals were visited at home by social
workers and invited to join the study. Participation
among the 1217 and 673 women invited from Thimphu
and Lungtenphu was 25.7% and 54.2%, respectively. 2)
In addition, women consulting outpatient clinics in the
two hospitals (mainly antenatal care or family planning
clinics in which cervical cancer screening is also offered
to women aged 20 or older), were also invited to join.
Participation among women invited through the hos-
pital was close to 100%.
Some limited sociodemographic information was ob-
tained from all women invited from home in Thimphu,
among whom non-participants tended to be younger
and more likely to be unmarried in comparison to par-
ticipants. Following signature of an informed consent
form, a structured questionnaire including information
on socio-demographic characteristics, sexual behaviour
of the women and of their partners, reproductive fac-
tors, use of contraceptive methods and smoking habits
was administered to all study participants. History of
HPV vaccination was asked to women aged ≤20 years.
A cytobrush (Cervex-Brush, Rovers Medical Devices B.V.,
The Netherlands) was used for the collection of exfoli-
ated cervical cells from the endocervix and ectocervix.
After preparation of a conventional Pap smear, the brush
containing cellular material was placed in a vial containing
PreservCyt medium (Cytyc, Boxbourough, MA, USA) and
stored at +4C until shipment.
Conventional Pap smears were read in the Department
of Cytology, JDWNRH, and reported according to the
2001 Bethesda System [4]. All women with abnormal cer-
vical findings were recalled to have a colposcope-aided
examination and, if necessary, a colposcopically-directed
biopsy and appropriate treatment by local gynaecologists.
Histological confirmation of cervical tissue was performed
at JDWNRH.
Women with CIN3 and ICC
Formalin-fixed paraffin-embedded biopsies were retrieved
from all cases of ICC and CIN3 diagnosed between 2010
and 2012 at JDWNRH, Thimphu or the Eastern Regional
Referral Hospital, Mongar. Biopsies were sent to the VU
University Medical Center, Amsterdam, for HPV DNA
testing and review of histology. After exclusion of 11 biop-
sies negative for beta-globin PCR and 177 biopsies without
any histological evidence of CIN3 or cancer, 211 CIN3
and 112 ICC cases were included in following analyses
(of which 17 CIN3 and 4 ICC, respectively, derived from
women included in the general population survey
described above).
HPV testing and genotyping
HPV testing was performed on all exfoliated cervical
cells and biopsies in the Department of Pathology at the
VU University Medical Center, Amsterdam. DNA was
extracted from the PreservCyt sample using magnetic
beads (Macherey-Nagel) on a robotic system (Hamilton
Robotics) according to the manufacturer’s instructions.
Biopsies were sectioned using a ‘sandwich’ approach,
whereby inner tumour sections were destined for HPV
testing and outer sections for histological confirmation of
tumour tissue (see above). One or more sections repre-
senting approximately 1 cm2 of tissue were predigested
with proteinase K after which DNA was extracted using
magnetic beads (Macherey-Nagel).
Beta-Globin PCR analysis was conducted first to confirm
the presence of human DNA in all specimens [5]. The
presence of HPV DNA was determined by conducting a
general primer GP5+/6+ −mediated PCR, which permits
the detection of a broad spectrum of genital HPV types
[6]. HPV positivity was assessed by hybridization of PCR
products in an enzyme immunoassay with 2 oligoprobe
cocktails that, together, detect the following 44 mucosal
HPV types: HPV6, 11, 16, 18, 26, 30, 31, 32, 33, 34, 35, 39,
40, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 64,
66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 85, 86, 89,
and 90. Subsequent HPV genotyping was conducted by
reverse-line blot hybridization of GP5+/6+ PCR products
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[7]. HPV types considered high-risk (HR) types for this
analysis comprised HPV16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, and 68 [8]; possible HR types comprised
HPV26, 30, 34, 53, 66, 67, 69, 70, 73, 82, and 85; all other
HPV types were considered low-risk (LR).
DNA extracted from cervical cells of women aged ≤
24 years, was additionally tested for the 13 HR types plus
HPV6 and 11 using an alternative PCR-based assay based
upon multiplex E7 gene PCR and DNA microarray [9] at
IARC. This assay has been validated against a WHO HPV
LabNet proficiency panel [10], and is known to be more
sensitive than GP5+/6 + −mediated PCR in detecting low
copy numbers of viruses, particularly in the presence of
multiple infections [11].
Statistical analyses
In addition to crude prevalence, age-standardised HPV
prevalence was computed using the world standardised
population to allow comparisons of HPV prevalence with
other IARC surveys [3]. Prevalence ratios (PR) for HPV
positivity and corresponding 95% confidence intervals (CI)
were computed using two binomial regression models with
a log link, the first adjusted for the study design variables
age group (<24; 25–29, 30–34, 35–39, 40–44, and >45 years)
and hospital where examined (JDWNRH or Lungthenphu),
and a second model that adjusted additionally for lifetime
sexual partners. Risk trends were assessed by considering
categories as continuous variables. PRs were also used to
compare HPV type-specific prevalence in HPV-positive
ICC and normal cytology.
Ethical approval
The present study had the approval of both the Research




Of the 2,525 participants who provided cervical cell sam-
ples, 2,505 had valid HPV results and were included in the
following analyses, including 1,638 and 867 recruited at
JDWNRH and Lungthenphu hospitals, respectively. Among
the 2,468 women with a valid PAP smear result, 196 (8%)
had an abnormal cytological diagnosis, including 123 (58%)
with atypical squamous cells of undetermined significance,
atypical squamous cells cannot exclude high-grade lesion
or atypical glandular cells of undetermined significance
(ASCUS/ASC-H/AGUS), 59 (2%) low-grade squamous
intraepithelial lesions (LSIL), and 14 (1%) high-grade squa-
mous intraepithelial lesions or worse (HSIL+). Histological
confirmation was obtained for 135 women with abnormal
cytology, among whom 23 CIN2, 24 CIN3 and 4 ICC were
histologically confirmed.
Overall HPV prevalence was 26% (95% CIs: 24–28),
being 23% (95% CIs: 21–25) among women with normal
cytology (Table 1). Corresponding overall HPV prevalence
age-standardised to the world population was 27%. The
prevalence of HPV types in abnormal cytology was 61%
(Table 1), being 52%, 81%, and 57% in ASCUS/ASC-H/
AGUS, LSIL and HSIL+, respectively. In total, 437 (17%)
women had single-type and 218 (9%) had multiple-type
infections. Crude and age-standardised prevalence of HR
types was 18%. Crude prevalence of possible HR HPV was
5%. HPV16 was the most common HPV type both in
women with normal (3%) and abnormal (14%) cytology.
Figure 1 shows the age-specific prevalence of HPV and
cytological abnormalities, classified hierarchically into (1)
HPV16 or 18, (2) other HR types and (3) LR types only.
Overall HPV prevalence was highest (33%, 95% CI: 30–36)
among women <24 years, and decreased with age, down
to 16% (95% CI: 11–22) among women aged ≥50 years.
Prevalence of cytological abnormalities varied between 4%
in women aged ≥50 years and 11% in women aged 40–44
years. The prevalence of CIN3 or worse was about 1% in
all age-groups, but all 4 ICC were diagnosed only in
women aged over 35 years old (data not shown).
Table 2 shows the relationship between HPV positivity
and various characteristics of participants. In a model
adjusted for age and hospital only, significant determinants
of HPV positivity included age group (PR for ≥45 vs ≤24
years = 0 · 53; 95% CI: 0 · 42–0 · 69), hospital (PR for
Lungthenphu versus JDWNRH=0 · 81; 95% CI: 0 · 70-0 · 94),
ethnic group (PR for Lhotsampa vs Scharchop = 0 · 69;
95% CI: 0 · 57–0 · 83), marital status (PR for separated/
widowed versus married = 1 · 34; 95% CI: 1 · 04–1 · 74),
number of marriages (PR for ≥2 vs 1 = 1 · 62; 95% CI: 1 ·
32–1.99), number of lifetime sexual partners (PR for ≥3 vs
1 = 1 · 93; 95% CI: 1 · 21–3.08), number of pregnancies
(PR for nulliparous vs 1 = 1 · 46; 95% CI: 1 · 23–1 · 74),
age at first pregnancy (PR for ≤22 vs <19 = 0 · 78; 95% CI:
0 · 63–0 · 95), husbands extramarital relations (PR for Yes,
during marriage = 1.71, 95% CI 1.27-2.31), use of any
contraceptive method (PR for ever vs never = 0 · 80;
95% CI: 0 · 69–0 · 93), history of PAP smear (PR = 0 · 77;
95% CI: 0 · 66-0 · 90), receiving cash for sex (PR = 2 · 77; 95%
CI: 1 · 55–4 · 95) or having genital warts (PR = 2 · 17; 95%
CI: 1 · 06–4 · 45). All these associations remained signifi-
cant in a second model additionally adjusted for lifetime
number of sexual partners, with the exception of number
of marriages.
No associations with HPV positivity were seen for edu-
cation level (49% of women reported no formal education),
source of recruitment (27% from home, 73% from hospital)
(Table 2), family income, smoking (11% ever smokers),
chewing of non-tobacco products (36% ever chewers), oc-
cupation (67% housewife), age at menarche (median =
14 years), age at first sexual intercourse (median = 19 years),
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and difference in age with partner at first sexual inter-
course (median = 4 years) (data not shown).
Upon additional testing of women aged ≤24 years with
multiplex E7 gene PCR (Figure 2), an additional 27 (3%)
and 79 (9%) women became positive for vaccine-targeted
HPV types and non-vaccine-targeted HR HPV types,
respectively. Very few GP5+/6+ positive women tested
negative by multiplex E7 PCR (2 and 13 for vaccine-
targeted HPV types and non-vaccinated HR HPV types,
respectively, data not shown). A small number of women
aged ≤20 years reported HPV vaccination (n = 34), among
whom the prevalence of non-vaccine targeted HR HPV
Table 1 Prevalence of human papillomavirus (HPV) types by cytological findings and overall among 2,505 women in
Bhutan, 2011-2012
HPV type Normal (n = 2272) Abnormal (n = 196) Total (n = 2505)a
Single Multiple Total (%) Single Multiple Total (%) Single Multiple Total (%)
HPV- - - 1750 (77) - - 76 (39) - - 1850 (74)
HPV+ 358 164 522 (23) 70 50 120 (61) 437 218 655 (26)
High-risk
16 48 30 78 (3.4) 15 13 28 (14) 65 44 109 (4.4)
18 26 27 53 (2.3) 2 9 11 (5.6) 29 37 66 (2.6)
31 14 7 21 (0.9) 4 3 7 (3.6) 19 10 29 (1.2)
33 9 12 21 (0.9) 6 4 10 (5.1) 16 17 33 (1.3)
35 3 6 9 (0.4) 3 2 5 (2.6) 6 8 14 (0.6)
39 11 5 16 (0.7) 0 6 6 (3.1) 11 11 22 (0.9)
45 9 19 28 (1.2) 1 8 9 (4.6) 10 27 37 (1.5)
51 15 14 29 (1.3) 6 8 14 (7.1) 21 22 43 (1.7)
52 16 12 28 (1.2) 3 3 6 (3.1) 19 15 34 (1.4)
56 17 14 31 (1.4) 4 8 12 (6.1) 21 23 44 (1.8)
58 14 13 27 (1.2) 11 6 17 (8.7) 25 19 44 (1.8)
59 21 19 40 (1.8) 4 2 6 (3.1) 26 21 47 (1.9)
68 4 5 9 (0.4) 3 1 4 (2.0) 7 6 13 (0.5)
Any 214b 125 339b (15) 62 42 104 (53) 282b 169 451b (18)
Possibly high-risk
26 1 1 2 (0.1) 0 0 0 (0.0) 1 1 2 (0.1)
30 3 7 10 (0.4) 1 1 2 (1.0) 4 8 12 (0.5)
34 0 1 1 (0.0) 0 0 0 (0.0) 0 1 1 (0.0)
53 2 4 6 (0.3) 1 2 3 (1.5) 3 6 9 (0.4)
66 4 13 17 (0.7) 0 3 3 (1.5) 4 16 20 (0.8)
67 15 24 39 (1.7) 1 9 10 (5.1) 17 33 50 (2.0)
69 0 3 3 (0.1) 0 1 1 (0.5) 0 4 4 (0.2)
70 8 13 21 (0.9) 0 2 2 (1.0) 8 15 23 (0.9)
73 1 5 6 (0.3) 0 2 2 (1.0) 1 7 8 (0.3)
82 2 2 4 (0.2) 1 1 2 (1.0) 3 3 6 (0.2)
85 0 1 1 (0.0) 0 1 1 (0.5) 0 2 2 (0.1)
Any 36 62 98 (4.3) 4 19 23 (11.7) 41 81 122 (4.9)
Low-risk
6 8 5 13 (0.6) 1 0 1 (0.5) 9 5 14 (0.6)
11 6 4 10 (0.4) 1 1 2 (1.0) 7 5 12 (0.5)
Other 94 99 193 (9.4) 2 24 26 (13) 98 125 223 (8.9)
Any 108 106 214 (9.4) 4 25 29 (17) 114 133 247 (10)
a37 inadequate cytology are also included in the total.
bThe total is not equal to the sum of the 13 high-risk because of 7 uncharacterized high-risk infections that are also included in the total.
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types (12%) was similar to that seen in unvaccinated
women of the same age, and that in women aged 21–24
(Figure 2). However, no infections with vaccine-targeted
HPV types were detected in vaccinated women, compared
to 6% in unvaccinated women of the same age (2-sided
Fisher’s exact test, P = 0 · 215), and 9% in women aged 21–24
(p = 0 · 064).
Women with CIN3 and ICC
Type-specific HPV prevalence is described in Table 3 for
biopsies of 211 CIN3 and 112 ICC cases of which 87% and
88%, respectively, were HPV-positive. Type-specific HPV
prevalence is reported among HPV-positive cases only
and is compared to that among 523 HPV-positive women
with normal cytology from the general population survey
(Table 3). HPV16 was by far the most common HPV type,
being detected in 60% and 63% of HPV-positive CIN3 and
ICC, respectively. HPV16/18 and HPV16/18/31/33/45/52/
58 together accounted for 70% and 88% of ICC, respect-
ively. Upon comparison with HPV-positive women with
normal cytology, PRs for women with ICC were 6.5 (95%
CI: 4.5–9.4) for HPV16 and 6.7 (95% CI: 3.8-12.1) for
HPV16/18/31/33/45/52/58, but did not exceed one for
any other HR HPV types. Possible HR, LR and multiple-
type infections were also much less common in ICC than
in HPV-positive women with normal cytology (Table 3).
HPV18 and HPV45 were detected in a larger proportion
of ICC than CIN3, whereas the opposite was true for
HPV58.
Discussion
These data provide a picture of HPV infection in the
adult female population of Bhutan just after the country
embarked upon a highly successful national programme
of HPV vaccination among 12–18 year old girls, to serve
as a baseline for future impact monitoring. Data repre-
sent that of an almost entirely vaccine-free population
and disclose a relatively high prevalence of HR HPV in-
fection (18%), particularly among women younger than
25 years (22%). Findings can be confidently compared
with other IARC HPV surveys that were conducted ac-
cording to a similar sampling and HPV testing protocol.
In this respect, the age-standardised HR HPV prevalence
in Bhutan (18%) ranks below that of Guinea (31%) [12]
and Mongolia (25%) [13], but is similar to the prevalence
detected in Nigeria (18%) [14] and Vanuatu (19%) [15].
It is more elevated than that found in many other areas
at high-risk for cervical cancer in Asia, including that in
neighbouring countries of India (12%) [16], China (12-13%)
[17-19] and Nepal (6%) [20]. HR HPV prevalence is
strongly correlated internationally with cervical cancer
incidence rates [21] and the high prevalence of cervical
carcinoma (1 out of every 200 women aged 35+ years) in
our study population is consistent with recent estimates of
cervical cancer incidence in Bhutan [1].
HPV16 was by far the most frequently detected type in
Bhutan, increasing from 3% of normal cytology up to 63%
of HPV-positive ICC. Such a high proportion of HPV16 in
cervical cancer agrees with findings of a meta-analysis in
which the proportion of HPV16-positive ICC in Western/
Central Asia (66%) was the highest among all world re-
gions [19]. Infections with vaccine types HPV16 and/or 18
accounted for 24% of HR HPV positivity in the general fe-
male population and for 70% of cervical cancer, which
gives an estimate of the potential future impact of the vac-
cine programme, if one simply assumes 100% efficacy and
zero cross-protection against non-vaccine types. The
proportion of ICC theoretically preventable by the seven
HR HPV types (HPV16/18/31/33/45/52/58) included in a
future nonavalent vaccine is 88%. Of note, HPV18 and
HPV45 were under-represented in CIN3 in comparison
to cancer, whereas certain HPV types, particularly HPV58,
were responsible for a much larger proportion of CIN3
than of ICC. These mirror findings from other world
regions in a recent meta-analysis [22].
Risk factors associated with cervical HPV infection
were largely consistent with previous IARC HPV Surveys.
Lifetime number of sexual partners was an important
Figure 1 Age-specific prevalence of human papillomavirus (HPV) DNA and of cytological abnormalities among 2,505 women. Bhutan,
2011–2012. HPV = human papillomavirus.
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Table 2 Prevalence ratios (PR) for human papillomavirus (HPV) positivity and corresponding 95% confidence intervals
(CIs) according to selected characteristics among 2,505 women in Bhutan, 2011-2012
Characteristic N womena HPV-positive (%) Adjustedb PR 95% CI Adjustedc PR 95% CI
Age-group (years)
≤24 885 289 (32.7) 1 - 1 -
25-34 852 223 (26.2) 0.82 0.71-0.95 0.81 0.70-0.94
35-44 435 85 (19.5) 0.61 0.49-0.75 0.57 0.46-0.71
≥45 333 58 (17.4) 0.53 0.42-0.69 0.51 0.39-0.65
χ21 for trend p < 0.001 p < 0.001
Hospital where examined
Thimphu 1638 460 (28.1) 1 - 1 -
Lungthenphu 867 195 (22.5) 0.81 0.70-0.94 0.82 0.71-0.95
Type of invitation
Clinic 1835 483 (26.3) 1 - 1 -
Door to door 670 172 (25.7) 1.06 0.91-1.24 1.08 0.92-1.26
Ethnic group
Scharchop 949 264 (27.8) 1 - 1 -
Ngalop 586 180 (30.7) 1.11 0.95-1.30 1.11 0.94-1.30
Lhotsampa 585 116 (19.8) 0.69 0.57-0.83 0.70 0.57-0.85
Other 371 88 (23.7) 0.90 0.74-1.11 0.89 0.72-1.09
Education (yrs)
Illiterate 1209 292 (24.2) 1 - 1 -
1-9 512 132 (25.8) 1.02 0.85-1.21 1.02 0.85-1.21
≥10 750 221 (29.5) 1.07 0.92-1.24 1.09 0.94-1.28
χ21 for trend p = 0.415 p = 0.274
Marital status
Married 2298 586 (25.5) 1 - 1 -
Single 54 19 (35.2) 1.22 0.84-1.76 1.60 1.14-2.24
Separated/widowed 137 42 (30.7) 1.34 1.04-1.74 1.31 1.01-1.69
Number of marriagesd
1 2209 549 (24.9) 1 - 1 -
≥2 201 67 (33.3) 1.62 1.32-1.99 1.27 0.86-1.86
Number of pregnancies
Nulliparous 276 117 (42.4) 1.46 1.23-1.74 1.50 1.26-1.78
1 776 228 (29.4) 1 - 1 -
2 588 134 (22.8) 0.85 0.70-1.03 0.83 0.68-1.01
≥3 839 163 (19.4) 0.84 0.67-1.05 0.81 0.65-1.01
χ21 for trende p = 0.159 p = 0.090
Age at first pregnancye
<19 554 145 (26.2) 1 - 1 -
19-21 885 222 (25.1) 0.93 0.78-1.11 0.98 0.82-1.17
≥22 754 155 (20.6) 0.78 0.63-0.95 0.81 0.66-0.99
χ21 for trend p = 0.014 p = 0.041
Contraceptive use
Never 562 173 (30.8) 1 - 1 -
Ever 1860 458 (24.6) 0.80 0.69-0.93 0.76 0.66-0.89
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determinant of HPV positivity, although the mean re-
ported number of women’s lifetime sexual partners (1.1)
was relatively low. Being single, separated or divorced, as
well as a history of receiving cash for sex (albeit rarely
reported), were also positively associated with HPV preva-
lence. Nulliparous women had a significantly higher risk
of being HPV-positive, even after adjustment, in agree-
ment with a pooled analysis of previous IARC HPV
Prevalence Surveys [23], but the linear trend by number of
pregnancies was not significant among parous women.
Use of both hormonal and non-hormonal contraceptives
and condoms were associated with lower HPV prevalence
in Bhutan, in contrast to previous findings of pooled
analyses of the IARC HPV prevalence surveys that found
no associations [23,24]. However, the effect of residual
confounding by under-reported high-risk sexual behaviour
on certain associations cannot be ruled out. Lastly, a lower
prevalence (20%) was also remarked among the Lhotsampa
ethnic group, who are an ethnically Nepalese and largely
Hindu population. However, this prevalence remains some-
what higher than that observed in the IARC HPV preva-
lence survey in Nepal (9%) [20].
Forty-five percent of study participants reported to
having a prior PAP smear, which gives an estimation of
the coverage of the cytology-based programme that has
been targeting women living in Thimphu since 1999.
Cervical screening is unavailable, however, in most rural
and higher-altitude areas of Bhutan. One possibility to
improve nationwide coverage is the application of an HPV
testing approach, e.g. careHPV in women aged 30 or older.
Our data suggest that approximately 15% of screened
women aged 30 or older might test positive for HR HPV
and require diagnostic follow-up and treatment.
This study has weaknesses and strengths. In particular,
the extent to which our study population is representa-
tive of the general female population in Thimphu, and
Bhutan as a whole, is difficult to evaluate. However,
HPV infection is asymptomatic and self-selection of
Table 2 Prevalence ratios (PR) for human papillomavirus (HPV) positivity and corresponding 95% confidence intervals
(CIs) according to selected characteristics among 2,505 women in Bhutan, 2011-2012 (Continued)
Hormonal only 853 233 (27.3) 0.82 0.69-0.96 0.78 0.66-0.92
Hormonal + other 276 63 (22.8) 0.79 0.61-1.02 0.74 0.57-0.95
Other only 777 174 (22.4) 0.78 0.65-0.94 0.75 0.63-0.90
Lifetime sexual partnersf
1 2228 566 (25.4) 1 - 1 -
2 180 60 (33.3) 1.54 1.24-1.92 1.54 1.24-1.92
≥3 26 10 (38.5) 1.93 1.21-3.08 1.93 1.21-3.08
χ21 for trend p < 0.001 p < 0.001
Husbands “extramarital” sexual relationshipsd
No 1966 481 (24.5) 1 - 1 -
Yes, before marriage only 308 95 (30.8) 1.30 1.08-1.55 1.23 1.02-1.48
Yes, during marriage 78 28 (35.9) 1.71 1.27-2.31 1.49 1.09-2.05
Uncertain 76 22 (29.0) 1.02 0.72-1.47 1.00 0.70-1.43
History of receiving cash for sexg
No 2467 641 (26.0) 1 - 1 -
Yes 9 5 (55.6) 2.77 1.55-4.95 - -
Last PAP smear (yrs)
Never 1367 418 (30.6) 1 - 1 -
Ever 1114 229 (20.6) 0.77 0.66-0.90 0.77 0.66-0.90
Evidence of genital warts at visith
No 2473 640 (25.9) 1 - 1 -
Yes 5 3 (60.0) 2.17 1.06-4.45 2.23 1.09-4.59
aSome figures do not add up to the total due to missing values.
bAdjusted for age and hospital as appropriate.
cAdjusted for age, hospital and lifetime sexual partners as appropriate.
dAmong ever married women only.
eAmong parous women only.
f3 virgins excluded.
gModel does not converge for PR adjusted for lifetime sexual partners.
hPR not adjusted for age because model does not converge.
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women by level of HPV risk is unlikely to have occurred.
Furthermore, there was no significant difference in HPV
prevalence by whether women were recruited through
hospital consultations or from their homes, neither was
there any substantial difference in their distribution of
any of the study variables in Table 1.
Strengths include the relatively large number of women,
especially those younger than 25 years, and the high rate
of colposcopical follow-up and histological confirmation
for women with abnormal cytology, allowing a strong gold
standard of disease ascertainment. Furthermore, we used
two high-quality PCR tests of which one, GP5+/6+, is
clinically validated and conducted in a central laboratory
that allows comparability with other studies, notably
previous IARC HPV Surveys.
We made a particular effort to sample a large number of
women aged ≤24 years, and to test with a second highly-
sensitive E7 multiplex PCR assay [9]. As expected, adding
this test approximately doubled the HR HPV prevalence
over that detected by GP5+/6+ [11]. The greater relative
Table 3 Prevalence of selected human papillomavirus (HPV) types and groups of HPV types among HPV-positive
women, by cervical status
HPV type Normala CIN3b Cancerb Cancer: normal cytology
(N = 2272) (N = 211) (N = 112) Prevalence ratio (95% CI)
n (% of HPV pos) n (% of HPV pos) n (% of HPV pos)
Any 522 - 183 - 99 - -
16 78 (15) 109 (60) 62 (63) 5.8 (4.0-8.3)
18 53 (10) 4 (2) 7 (7) 0.7 (0.4-1.5)
16/18 127 (24) 113 (62) 69 (70) 5.0 (3.4-7.4)
31 21 (4) 14 (8) 4 (4) 1.0 (0.4-2.5)
33 21 (4) 12 (7) 2 (2) 0.5 (0.1-2.0)
45 28 (5) 2 (1) 5 (5) 0.9 (0.4-2.2)
52 28 (5) 2 (1) 3 (3) 0.6 (0.2-1.8)
58 27 (5) 32 (18) 5 (5) 1.0 (0.4-2.2)
16/18/31/33/45/52/58 235 (45) 168 (92) 87 (88) 6.7 (3.8-12.1)
Other high-risk types 104 (20) 11 (6) 9 (9) 0.4 (0.2-0.8)
Possible high-risk types 98 (19) 4 (2) 4 (4) 0.2 (0.1-0.6)
Low-risk types 214 (41) 8 (4) 5 (5) 0.1 (0.0-0.2)
Multiple infections 164 (31) 16 (9) 6 (6) 0.2 (0.1-0.4)
aHPV tested in cervical cells from women diagnosed with normal cytology from general population survey.
bHPV tested in biopsies from women diagnosed with histologically confirmed CIN3 and ICC from case series.
Figure 2 Age-specific prevalence of human papillomavirus (HPV) DNA among 885 women ≤24 years old, according to two HPV DNA
tests (GP5+/6+ and multiplex E7). Bhutan, 2011–2012. HPV = human papillomavirus; HR = high-risk.
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increase for non-vaccine-targeted than vaccine-targeted
types is likely because the former have more mismatches
with both GP-PCR primers [5].
This baseline survey represents the first part of a long-
term protocol to monitor HPV vaccine impact in Bhutan,
which will include a repeat HPV prevalence survey in cervi-
covaginal samples in 2016/17 among women aged ≤24 years
to demonstrate the 5-year impact of the HPV vaccination
programme, as well as repeated HPV prevalence surveys in
urine samples of adolescents aged 17–19 years at high-
schools in Thimphu, Bhutan.
Conclusions
These data will serve as a robust baseline for future evalu-
ations of HPV vaccine programme effectiveness on HPV
prevalence as cohorts of vaccinated girls grow up. Never-
theless, our survey did also capture a few young vacci-
nated women in the baseline survey, among whom there
was a very reassuring, albeit statistically weak, evidence
of 100% protection against vaccine-targeted HPV type
(HPV6/11/16/18) infection, irrespective of the HPV test.
Whilst awaiting more statistically robust evaluations in the
future, this ad hoc finding represents the first ever real-life
evidence of HPV vaccination programme impact in a low-
or middle-income country.
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